Assessment of the efficacy of hepatitis C treatment in Hospital Universiti Sains Malaysia (HUSM)
Year: 2019
Type: dissertation
Study design: Observational Study
Abstract: Background : Management of Hepatitis C virus (HCV) infection has been evolved in the \nlast few years. Currently, the newer treatment direct acting antivirals (DAAs) promise a \nhigher rate of efficacy to compare to previous treatment, pegylated interferon. The goal \nof HCV treatment is to eradicate the virus and to avoid the progression of liver fibrosis \nand HCV-related disease. Sustained virologic response (SVR) is the most widely used \nefficacy endpoint in clinical studies of hepatitis C and represents the eradication of HCV \nfrom the body. We conduct a study to compare the efficacy of Hepatitis C treatment \nbetween pegylated interferon and DAA, it effects towards liver function and its \nassociated factors in our cohort of patient therefore, support our continuing use of DAA \nin the treatment of Hepatitis C virus infection in HUSM. \nMethodology: This is a retrospective record review done by reviewing a record of 88 \npatients who were either on Pegylated Interferon or on DAAs during the period of 2011 till \n2018. Subjects were who achieved undetectable viral load in serum after 12 or 24 weeks \nafter completed therapy was taken as a sustained virological response (SVR). We also \nevaluated the variation of ALT at baseline and 12 weeks after completed therapy. All \nrelevant data are gathered and recorded in statistical software for analysis. \nResult: Between January 2011 and September 2018, 35 patients started a DAA treatment \nand 53 patients had completed pegylated interferon treatment. Overall proportion of \nSVR12 was 92% (n=32) for DAAs and 69.8%(n=37) for interferon-based treatment. \nAnalysis of ALT showed that the level normalized in the most patients who had achieved \nSVR (68%). Factors such as gender, genotype, race, pre-treatment HCV RNA level and \nliver cirrhosis are shown not to be associated with the efficacy of treatment. \nConclusion : Achievement of the high rate of SVR represents the goal for HCV treatment \nand has implications to reduce risk of liver disease progression and extrahepatic disease. \nHowever, further studies are needed to include more patients in order to improve power of \nthe study. Based on the higher rate of SVR associated with DAA therapy, this should be \nthe first choice of treatment.
Author: Ahmad Syahidan Yusoff
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3202655920